InsidersTradesSigma
申报总数
公司
▲ 买入（1 笔）
▼ 卖出（6 笔）
内部人交易记录
高级管理人员已披露买入
1
已披露卖出
6
T+90 胜率
100%
T+90 平均收益
+12.1%
基于 1 个已确定 T+90 收益的买入信号。收益基准：公布次日的收盘价。
信号历史
Browse the full record of transactions filed by Greenleaf Peter, Director. Insider active across 4 companies, notably Pelthos Therapeutics Inc.. Aggregated, 20 disclosures have been recorded. Split: 1 buy · 6 sells. Total volume traded: €977k. Activity tracked since 11 May 2021. The latest transaction was disclosed on 2 July 2026 (Cession). Regulator: SEC (Form 4). The full history is accessible without signup.
Companies and markets linked to Greenleaf Peter
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报20 总计
712 股@ US$25.99540.021% mcap88.9% 占其流量Common StockSEC:0001919246-26-000100:0
85 股@ US$27.27330.0026% mcap11.1% 占其流量Common StockSEC:0001919246-26-000100:1
420 股@ US$20.515122.8% 占其流量Common StockSEC:0001919246-26-000052:0
377 股@ US$21.361421.4% 占其流量Common StockSEC:0001919246-26-000052:1
25,478 股0Common StockSEC:0001919246-26-000043:0
196,403 股0Common StockSEC:0001600620-26-000021:0
100,171 股@ US$14.4056.5% 占其流量Common StockSEC:0001363683-26-000002:0
165,384 股0Common StockSEC:0001600620-26-000002:0
290,728 股0Common StockSEC:0001600620-25-000024:0
126,981 股@ US$5.6068.0% 占其流量Common StockSEC:0001600620-24-000038:0
661,538 股0Common StockSEC:0001600620-24-000017:0
33,047 股@ US$8.7828.3% 占其流量Common StockSEC:0001600620-24-000013:0
667,407 股Common StockSEC:0001628280-23-006526:0
30,220 股@ US$5.6046.0% 占其流量Common StockSEC:0000899243-22-019780:0
105,034 股0Common StockSEC:0001103021-22-000067:0
28,300 股0Common StockSEC:0001628280-22-005123:0
10,246 股0Common StockSEC:0001103021-22-000021:0
35,000 股0Common StockSEC:0001103021-21-000070:0
25,452 股@ US$4.4237.0% 占其流量Common StockSEC:0001209191-21-040329:0
2,133 股@ US$10.150.8% 占其流量Common StockSEC:0001628280-21-010022:0
标准退出：2021年8月9日 (T+90)
20 条申报中的 20 条
About Greenleaf Peter
Peter Greenleaf is a Director and Chief Executive Officer of Pelthos Therapeutics Inc., Aurinia Pharmaceuticals Inc., and ANTARES PHARMA, INC. He leads these companies with a focus on innovation and the development of new treatments.
